CY1126127T1 - Παρασκευασμα που περιεχει γαλακτοβακιλλους reuteri και κιτρικο οξυ για ιατρικη χρηση - Google Patents
Παρασκευασμα που περιεχει γαλακτοβακιλλους reuteri και κιτρικο οξυ για ιατρικη χρησηInfo
- Publication number
- CY1126127T1 CY1126127T1 CY20231100325T CY231100325T CY1126127T1 CY 1126127 T1 CY1126127 T1 CY 1126127T1 CY 20231100325 T CY20231100325 T CY 20231100325T CY 231100325 T CY231100325 T CY 231100325T CY 1126127 T1 CY1126127 T1 CY 1126127T1
- Authority
- CY
- Cyprus
- Prior art keywords
- bacteria
- relates
- citric acid
- preparation containing
- medical use
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 title 3
- 241000186604 Lactobacillus reuteri Species 0.000 title 1
- 229940001882 lactobacillus reuteri Drugs 0.000 title 1
- 241000894006 Bacteria Species 0.000 abstract 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 2
- 235000014655 lactic acid Nutrition 0.000 abstract 2
- 239000004310 lactic acid Substances 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- Polymers & Plastics (AREA)
- Physiology (AREA)
- Food Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με μεθόδους ενεργοποίησης ζωντανών βακτηρίων γαλακτικού οξέος, που περιλαμβάνουν την έκθεση των εν λόγω βακτηρίων σε ένα παρασκεύασμα που περιλαμβάνει κιτρικό άλας, όπου τα εν λόγω βακτήρια έχουν την ικανότητα να χρησιμοποιούν το κιτρικό άλας ως εξωτερικό δέκτη ηλεκτρονίων. Η παρούσα εφεύρεση σχετίζεται περαιτέρω με μεθόδους για την ενίσχυση της δραστηριότητας συγκεκριμένων ζωντανών βακτηρίων σε θηλαστικά. Πιο συγκεκριμένα, η εφεύρεση σχετίζεται με τρόπους για τη βελτίωση της αφύπνισης συγκεκριμένων βακτηρίων γαλακτικού οξέος από την κρυοξηραμένη κατάσταση. Η παρούσα εφεύρεση σχετίζεται επίσης με παρασκευές που περιλαμβάνουν τα εν λόγω ενεργοποιημένα βακτήρια και θεραπευτικές χρήσεις των εν λόγω ενεργοποιημένων βακτηρίων.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562103201P | 2015-01-14 | 2015-01-14 | |
PCT/EP2016/050694 WO2016113363A1 (en) | 2015-01-14 | 2016-01-14 | A method of activating lactic acid bacteria |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1126127T1 true CY1126127T1 (el) | 2023-11-15 |
Family
ID=55129894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20231100325T CY1126127T1 (el) | 2015-01-14 | 2023-07-11 | Παρασκευασμα που περιεχει γαλακτοβακιλλους reuteri και κιτρικο οξυ για ιατρικη χρηση |
Country Status (17)
Country | Link |
---|---|
US (1) | US20170304376A1 (el) |
EP (1) | EP3244903B1 (el) |
JP (1) | JP6837442B2 (el) |
CN (1) | CN107427461B (el) |
AU (1) | AU2016208007B2 (el) |
BR (1) | BR112017014192B1 (el) |
CA (1) | CA2972963C (el) |
CL (1) | CL2017001722A1 (el) |
CY (1) | CY1126127T1 (el) |
ES (1) | ES2952585T3 (el) |
HK (1) | HK1247561A1 (el) |
HR (1) | HRP20230639T1 (el) |
HU (1) | HUE062482T2 (el) |
MX (1) | MX2017009247A (el) |
PL (1) | PL3244903T3 (el) |
RS (1) | RS64392B1 (el) |
WO (1) | WO2016113363A1 (el) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019060661A1 (en) * | 2017-09-22 | 2019-03-28 | Iowa State University Research Foundation, Inc. | PROBIOTIC COMPOSITIONS FOR THE PRODUCTION OF DOPAMINE |
WO2020004933A1 (ko) * | 2018-06-26 | 2020-01-02 | 씨제이제일제당 (주) | 구연산염을 포함하는 유산균 동결 보호용 조성물 |
CN110320840B (zh) * | 2019-07-11 | 2021-06-22 | 四川长虹网络科技有限责任公司 | 一种可降低物联网产品电池电量消耗的方法及*** |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3436581B2 (ja) * | 1994-03-18 | 2003-08-11 | 雪印乳業株式会社 | 乳糖分解酵素活性の高い菌体の製造法 |
US6506413B1 (en) * | 2001-04-30 | 2003-01-14 | Joseph C. Ramaekers | Compositions for treating animal diseases and syndromes |
US20030017192A1 (en) * | 2001-06-19 | 2003-01-23 | Hanny Kanafani | Process for producing extended shelf-life ready-to-use milk compositions containing probiotics |
JP3957132B2 (ja) * | 2001-09-07 | 2007-08-15 | キッコーマン株式会社 | 低濁性醤油乳酸菌の分離用培地、同培地を用いる低濁性醤油乳酸菌の分離法及び同乳酸菌を用いる清澄度の高い醤油の製造法 |
FR2859217B1 (fr) * | 2003-09-03 | 2005-11-11 | Rhodia Chimie Sa | Activateur pour ferment a base de bacteries lactiques et procede de preparation d'un produit mettant en oeuvre ledit activateur |
JP2007330157A (ja) * | 2006-06-15 | 2007-12-27 | Obihiro Univ Of Agriculture & Veterinary Medicine | 乳酸菌及び乳酸菌由来物の癌細胞増殖抑制作用および炎症性サイトカイン抑制作用を測定する方法 |
US8617537B2 (en) * | 2008-06-10 | 2013-12-31 | Biogaia Ab | Controlled activation of the reuterin-production machinery of lactobacillus |
FR2967070B1 (fr) * | 2010-11-05 | 2013-07-05 | Oreal | Acide gras monoinsature pour prevenir et/ou traiter les imperfections du teint de la peau |
EP2408171A1 (en) * | 2010-07-16 | 2012-01-18 | Research In Motion Limited | Application programming interface for mapping application |
CA2822660C (en) * | 2010-12-31 | 2021-09-07 | Abbott Laboratories | Synbiotic combination of probiotic and human milk oligosaccharides |
JP5622110B2 (ja) * | 2011-02-21 | 2014-11-12 | 株式会社農 | 新規乳酸菌 |
JP6051112B2 (ja) * | 2013-06-05 | 2016-12-27 | 公立大学法人大阪府立大学 | 白金族金属の回収方法 |
CN104206539A (zh) * | 2014-08-14 | 2014-12-17 | 澳优乳业(中国)有限公司 | 一种益生菌婴幼儿奶粉 |
-
2016
- 2016-01-14 HU HUE16700501A patent/HUE062482T2/hu unknown
- 2016-01-14 CA CA2972963A patent/CA2972963C/en active Active
- 2016-01-14 EP EP16700501.6A patent/EP3244903B1/en active Active
- 2016-01-14 JP JP2017555837A patent/JP6837442B2/ja active Active
- 2016-01-14 AU AU2016208007A patent/AU2016208007B2/en active Active
- 2016-01-14 RS RS20230608A patent/RS64392B1/sr unknown
- 2016-01-14 BR BR112017014192-2A patent/BR112017014192B1/pt active IP Right Grant
- 2016-01-14 WO PCT/EP2016/050694 patent/WO2016113363A1/en active Application Filing
- 2016-01-14 US US15/320,996 patent/US20170304376A1/en active Pending
- 2016-01-14 MX MX2017009247A patent/MX2017009247A/es unknown
- 2016-01-14 PL PL16700501.6T patent/PL3244903T3/pl unknown
- 2016-01-14 CN CN201680005682.2A patent/CN107427461B/zh active Active
- 2016-01-14 ES ES16700501T patent/ES2952585T3/es active Active
- 2016-01-14 HR HRP20230639TT patent/HRP20230639T1/hr unknown
-
2017
- 2017-06-28 CL CL2017001722A patent/CL2017001722A1/es unknown
-
2018
- 2018-05-30 HK HK18107030.7A patent/HK1247561A1/zh unknown
-
2023
- 2023-07-11 CY CY20231100325T patent/CY1126127T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2016113363A1 (en) | 2016-07-21 |
CN107427461B (zh) | 2021-04-13 |
ES2952585T3 (es) | 2023-11-02 |
EP3244903A1 (en) | 2017-11-22 |
PL3244903T3 (pl) | 2023-08-14 |
EP3244903C0 (en) | 2023-06-07 |
AU2016208007A1 (en) | 2017-07-06 |
JP6837442B2 (ja) | 2021-03-03 |
US20170304376A1 (en) | 2017-10-26 |
EP3244903B1 (en) | 2023-06-07 |
JP2018503684A (ja) | 2018-02-08 |
HK1247561A1 (zh) | 2018-09-28 |
CN107427461A (zh) | 2017-12-01 |
AU2016208007B2 (en) | 2021-09-09 |
CL2017001722A1 (es) | 2018-04-06 |
RS64392B1 (sr) | 2023-08-31 |
HUE062482T2 (hu) | 2023-11-28 |
BR112017014192A2 (pt) | 2018-03-06 |
BR112017014192B1 (pt) | 2022-02-01 |
CA2972963C (en) | 2023-03-14 |
HRP20230639T1 (hr) | 2023-09-29 |
MX2017009247A (es) | 2017-10-12 |
CA2972963A1 (en) | 2016-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1126127T1 (el) | Παρασκευασμα που περιεχει γαλακτοβακιλλους reuteri και κιτρικο οξυ για ιατρικη χρηση | |
CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
CY1119058T1 (el) | Ενωσεις ιμιδαζοπυρρολιδινονης | |
CY1119123T1 (el) | Δις-αρυλοσυζευγμενες αρυλοτριαζολονες και η χρηση τους | |
CY1124548T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου | |
CY1119676T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπεια του καρκινου | |
CY1119957T1 (el) | Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος | |
CY1121849T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου | |
CY1123963T1 (el) | Καινοτομα πολυμερικα προφαρμακα hgh | |
GT201500011A (es) | Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso | |
MD3250182T2 (ro) | Compoziții dispersabile | |
CY1123532T1 (el) | Αναστολεις του gingipain λυσινης | |
JO3543B1 (ar) | تراكيب حمض أميني إصدار معدل تعطى عن طريق الفم | |
CY1122114T1 (el) | Καταπινομενα δισκια ν-ακετυλοκυστεϊνης | |
CY1123366T1 (el) | Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου | |
BR112016023613A2 (pt) | novo bacteriófago e composição compreendendo o mesmo | |
CY1117881T1 (el) | Στερεες φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα βιοπτερινης και χρησεις αυτων των συνθεσεων | |
CY1122882T1 (el) | Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου | |
CY1122892T1 (el) | Παραγωγα 3-(καρβοξυμεθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου | |
CY1122473T1 (el) | Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης | |
CY1123877T1 (el) | Μορφες στερεας καταστασης αλατων νιλοτινιμπης | |
EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
BR112018071363A2 (pt) | composições farmacêuticas orais de nicotinamida | |
PH12018550097A1 (en) | Infant formula comprising human milk peptides | |
BR112014024033A8 (pt) | Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes |